$46.33 0.00 (0%)
2/13/2012 4:01 PM

Covance, Inc. (NYSE:CVD)

CAPS Rating: 3 out of 5

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Recs

1
Player Avatar 97E3LPL (72.07) Submitted: 12/16/2008 9:12:50 AM : Outperform Start Price: $39.63 CVD Score: +0.49

Pharma is among the least affected industries, however they are seeking cost reductions, effiiciency gains, etc like everyone else. The usual and likely avenue for that is CROs, and if you read the news for this company, they are already reeping rewards.

Report this Post Add Comment

Featured Broker Partners


Advertisement